During the past decade, Retina Institute of Virginia conducted 18 clinical trials. In the 10-year time frame, 18 clinical trials started and 12 clinical trials were completed, i.e. on average, 66.7% percent of trials that started reached the finish line to date. In the past 5 years, 8 clinical trials started and 10 clinical trials were completed. i.e. 125% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Retina Institute of Virginia" #1 sponsor was "Hoffmann-La Roche" with 7 trials, followed by "Jaeb Center for Health Research" with 5 trials sponsored, "Allergan" with 2 trials sponsored, "Kodiak Sciences Inc" with 2 trials sponsored and "Clearside Biomedical, Inc." with 2 trials sponsored. Other sponsors include -2 different institutions and companies that sponsored additional 8 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Retina Institute of Virginia" #1 collaborator was "National Eye Institute (NEI)" with 4 trials as a collaborator, "Regeneron Pharmaceuticals" with 3 trials as a collaborator, "Genentech, Inc." with 2 trials as a collaborator, "National Institutes of Health (NIH)" with 2 trials as a collaborator and "Allergan" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 7 trials.

According to Clinical.Site data, the most researched conditions in "Retina Institute of Virginia" are "Diabetic Macular Edema" (9 trials), "Geographic Atrophy" (4 trials), "Macular Degeneration" (4 trials), "Diabetic Retinopathy" (3 trials) and "Macular Edema" (2 trials). Many other conditions were trialed in "Retina Institute of Virginia" in a lesser frequency.

Most popular intervention types in "Retina Institute of Virginia" are "Drug" (20 trials), "Other" (5 trials), "Procedure" (4 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Sham Procedure" (5 trials), "Aflibercept" (3 trials), "Deferred aflibercept" (2 trials), "Deferred laser" (2 trials) and "Faricimab" (2 trials). Other intervention names were less common.

The vast majority of trials in "Retina Institute of Virginia" are 20 trials for "All" genders.

Currently, there are NaN active trials in "Retina Institute of Virginia". undefined are not yet recruiting, 1 are recruiting, 6 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 9 completed trials in Retina Institute of Virginia, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Retina Institute of Virginia, 0 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 16 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".